Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cannabinoid Clear all
Completed Phase 2 Interventional Results available

Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)

NCT01253408
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Sep 2, 2026, 3:42 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II

NCT02710097
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active inhaled cannabis, Placebo, Active Oral Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 3:42 AM EDT
Not listed No phase listed Observational

Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma

NCT05520294
View directory record Official record
Conditions
Melanoma
Interventions
High-performance liquid chromatography-tandem mass spectrometry assays
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 100 Years
Enrollment
90 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 2, 2026, 3:42 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

NCT07726069
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Haloperidol
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Results available

Opioid and Cannabinoid Pharmacokinetic Interactions

NCT00308555
View directory record Official record
Conditions
Pain
Interventions
Cannabis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2

NCT00598286
View directory record Official record
Conditions
CB1, Cannabinoid, PET, Brain Imaging
Interventions
[18F]FMPEP-d2
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 2, 2026, 3:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alcohol and Cannabis Co-Use and the Gut-Brain Axis

NCT04998006
View directory record Official record
Conditions
Cannabis Use, Alcohol Use, Inflammation
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional

A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

NCT05935891
View directory record Official record
Conditions
Musculoskeletal Syndrome
Interventions
CBD-dominant, THC dominant
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Results available

Opioid and Cannabinoid Interactions

NCT03705559
View directory record Official record
Conditions
Marijuana Usage, Opioid Use
Interventions
Vaporized Marijuana, Opioid Agonist, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 2, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

NCT04436081
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior
Interventions
THC-free CBD Oil, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Brain Imaging of Cannabinoid Receptors

NCT03204305
View directory record Official record
Conditions
Cannabis Use Disorder, Cannabis Dependence, Continuous
Interventions
11C-OMAR, Cannabis
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Marijuana and Opioids

NCT05485012
View directory record Official record
Conditions
Marijuana Use, Opioid Use
Interventions
Marijuana, Opioid
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Modulation of Pain

NCT01595620
View directory record Official record
Conditions
Pain
Interventions
Thermal, Electrical, Capsaicin, THC, Placebo
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Impact of Cannabinoids on Menopause Symptoms

NCT06831916
View directory record Official record
Conditions
Perimenopause, Menopause
Interventions
Active Cannabinoid Product, Placebo
Dietary Supplement · Other
Lead sponsor
Washington State University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Receptor Function & Alcoholism

NCT00624715
View directory record Official record
Conditions
Alcoholism
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

NCT02177513
View directory record Official record
Conditions
Cannabis Use
Interventions
Placebo + Placebo, Oral Cannabis + Placebo, Placebo + Inhaled Cannabis, Placebo + Smoked Cannabis, 6.9% cannabis oral
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoids and Cerebellar-Motor Functioning

NCT01853020
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 35 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

NCT04201197
View directory record Official record
Conditions
Drug-Interactions
Interventions
Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

NCT05632627
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

NCT00656487
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal
Interventions
rimonabant, placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
21 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 2, 2026, 3:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoid Augmentation of Fear Response in Humans

NCT01665573
View directory record Official record
Conditions
Fear Conditioning
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 2, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

NCT03202303
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cannabidivarin, Matched Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 2, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 3:42 AM EDT